+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 129 Actively Recruiting clinical trials

L

Actively Recruiting

Researchers are evaluating the long-term safety and tolerability of intermittent use of elismetrep for treating acute migraine attacks. This Phase 3 study compares two doses of elismetrep, 10 mg and 20 mg, to understand their safety profiles over an average of one year. The study involves adult participants who have previously used elismetrep in an acute treatment trial and met compliance requirements. Participants are randomly assigned to receive either 10 mg or 20 mg of elismetrep taken orally during migraine attacks. The study uses a triple-masked design to ensure unbiased results. The treatment period spans approximately one year, during which safety and adverse events are closely monitored. This includes tracking any adverse events leading to discontinuation or serious adverse events related to the study drug. During the study, participants will complete electronic diaries to record migraine episodes and medication use. They will also attend scheduled visits to assess safety and tolerability, including monitoring for adverse events. The research team will measure the proportion of participants experiencing treatment-emergent adverse events and serious adverse events through study completion. Participants are expected to use a personal smartphone to maintain study diaries and comply with study procedures throughout the study duration.

Age: 18Years +All GendersPhase 3
113 locations
P

Actively Recruiting

Researchers are evaluating zelquistinel, a drug aimed at reducing symptoms of major depressive disorder in adults aged 18 to 64 years. This Phase 2 clinical trial compares the effects and safety of zelquistinel to a placebo in participants diagnosed with major depressive disorder. The study will focus on changes in depression severity and monitor any medical issues that arise during treatment. Participants will take one tablet of either zelquistinel or placebo once a week for six weeks. The trial includes a screening period of up to 28 days, followed by a 42-day treatment phase, and then a four-week follow-up period. During treatment, participants will visit the clinic weekly to receive their dose and have their depression symptoms assessed using the Hamilton Depression Rating Scale-17. Throughout the study, participants will have their depression severity regularly evaluated, along with monitoring for adverse events or side effects. The study lasts up to 98 days, including screening, treatment, and follow-up. Researchers will measure changes in depression scores from the beginning to the end of treatment and monitor overall safety during this time.

Age: 18Years - 64YearsAll GendersPhase 2
32 locations
C

Actively Recruiting

Researchers are comparing two chemotherapy approaches combined with standard surgery and radiation in patients newly diagnosed with intermediate-risk rhabdomyosarcoma. This phase III trial evaluates whether a higher dose chemotherapy over a shorter time performs better or differently than a lower dose chemotherapy with maintenance over a longer period. The study also examines survival rates, treatment side effects, and molecular features of the cancer. Participants are randomly assigned to one of two treatment regimens. Regimen A involves vincristine, dactinomycin, and a higher dose of cyclophosphamide given intravenously over multiple 21-day cycles, with possible surgery in week 12 and radiation during later cycles. Regimen B uses a lower cyclophosphamide dose alternating with vincristine and irinotecan, followed by 24 weeks of maintenance chemotherapy with vinorelbine and oral cyclophosphamide. Both groups undergo imaging scans and may have biopsies during the study. Throughout the trial, participants attend scheduled visits for chemotherapy administration, imaging CT, MRI, PET, blood and other sample collections, and monitoring of side effects. After treatment, follow-up visits occur every 3 months for the first year, then less frequently over 5 years. Researchers measure event-free survival, overall survival, local tumor control, treatment-related adverse events, and timely molecular biomarker reporting. Biospecimens are collected for future research and fertility preservation is assessed.

Age: 0 - 50YearsAll GendersPhase 3
87 locations
P

Actively Recruiting

Researchers are evaluating the best way to combine chemotherapy and radiation therapy for children and young adults with localized non-germinomatous germ cell tumors NGGCT in the brain. The study aims to optimize radiation treatment for patients who respond well to initial chemotherapy and to use higher dose chemotherapy followed by radiation for those who do not respond as well. This phase II trial focuses on how tumors respond to initial chemotherapy to decide the next treatment steps, aiming to reduce side effects and improve disease control. Participants receive induction chemotherapy with drugs like carboplatin, etoposide, ifosfamide, and thiotepa over up to six cycles, repeated every 21 days if no disease progression occurs. Based on their response, patients are assigned to one of two plans Plan A involves radiation therapy to the ventricles and spinal canal WVSCI, while Plan B includes high-dose chemotherapy with stem cell transplant followed by craniospinal radiation. Some patients may undergo second-look surgery to guide treatment decisions. During the study, participants have MRIs, cerebrospinal fluid and blood samples collected, and complete questionnaires assessing cognitive and behavioral functions. Researchers monitor tumor response, progression-free survival, overall survival, and side effects over up to 10 years. The study also compares outcomes based on radiation type and its effects on growth and blood counts, aiming to improve long-term quality of life for patients.

Age: 3Years - 29YearsAll GendersPhase 2
170 locations
P

Actively Recruiting

Researchers are evaluating BMS-986488, alone and in combination with other drugs, in patients with advanced malignant tumors. This early-phase study aims to determine if these treatments are safe, tolerable, and show anti-cancer activity in various solid tumor types, including clear-cell renal cell carcinoma, ovarian cancer, non-small cell lung cancer, colorectal cancer, and pancreatic ductal adenocarcinoma. The study is sponsored by Bristol-Myers Squibb and involves participants with specific tumor mutations and measurable disease. Participants receive BMS-986488 as monotherapy or combined with adagrasib, cetuximab, or nivolumab in different parts of the study. Dosing schedules involve specified doses on particular days, with study parts designed to assess different drug combinations. The trial follows a sequential model without randomization or masking. During the study, participants are monitored for adverse events, serious adverse events, and dose-limiting toxicities up to approximately 100 days after the last dose. Researchers assess drug concentrations through blood tests and evaluate tumor response and disease control over up to 52 weeks after treatment ends. The total participation duration may vary depending on treatment cycles and follow-up assessments.

Age: 18Years +All GendersPhase 1
8 locations
E

Actively Recruiting

Researchers are evaluating combination chemotherapy treatments for patients with newly diagnosed diffuse anaplastic Wilms tumors DAWT and relapsed favorable histology Wilms tumors FHWT. This phase II trial aims to compare different chemotherapy regimens to see if adding drugs like vincristine and irinotecan improves survival outcomes for these patients, based on historical data. The study also explores kidney toxicity, genetic factors, and surgical outcomes related to these tumors. Patients are assigned to one of two treatment groups. Arm I Regimen UH-3 involves multiple cycles of vincristine, doxorubicin, cyclophosphamide, carboplatin, etoposide, and irinotecan administered intravenously every 21 days with radiation therapy as needed. Arm II Regimen ICECycloTopo includes cycles of carboplatin, etoposide, ifosfamide, cyclophosphamide, and topotecan given intravenously every 21 days with surgery andor radiation as clinically indicated. Both groups undergo various imaging scans and biopsies throughout treatment. Participants are closely monitored with CT, PET, X-rays, MRI, ultrasound, bone scans, blood tests, and biopsies during the trial. After treatment, follow-up visits occur every 3 months for the first two years, then every 6 months for years 3 and 4, and once at year 5. The primary outcomes measured are event-free survival and overall survival up to five years. The study also collects blood, urine, and tumor tissue samples for future research and monitors treatment side effects and kidney function.

Age: 0 - 30YearsAll GendersPhase 2
205 locations
S

Actively Recruiting

Researchers are evaluating the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate targeting EGFR and HER3 with a chemotherapy payload, compared to treatment chosen by physicians including paclitaxel, nab-paclitaxel, carboplatin plus gemcitabine, and capecitabine for patients with first-line metastatic triple-negative breast cancer TNBC or low estrogen receptor ER-low, HER2-negative breast cancer who cannot receive anti-PDL1 or endocrine therapies. This study includes adults with locally advanced, recurrent inoperable, or metastatic disease who meet specific eligibility criteria. Participants are randomly assigned to receive iza-bren or one of the physicians choice chemotherapy regimens. The treatments are given at specified doses on scheduled days. The study includes two phases Phase 2 to determine the recommended dose of iza-bren and Phase 3 to compare progression-free survival and other outcomes. The study will last several years, with follow-up extending up to approximately 47 months after randomization. During the study, participants will undergo regular assessments including imaging scans to measure tumor response, laboratory tests, and monitoring for adverse events. Quality of life questionnaires will also be completed. Researchers will track progression-free survival, overall survival, treatment-related side effects, tumor size changes, and patient-reported outcomes to evaluate the treatments. The total participation duration may extend up to several years depending on treatment response and follow-up requirements.

Age: 18Years +All GendersPhase 2Phase 3
295 locations
E

Actively Recruiting

Researchers are evaluating the use of nipocalimab in pregnant individuals at risk for severe Hemolytic Disease of the Fetus and Newborn HDFN. The study aims to compare nipocalimab with a placebo to see if it can reduce the risk of fetal anemia, a condition where the babys red blood cell levels drop too low during pregnancy. This phase 3, randomized, placebo-controlled, and triple-blind study is conducted across multiple centers. Participants will receive either nipocalimab or a matching placebo through weekly intravenous infusions starting from randomization until 35 weeks of gestational age. The study groups include an experimental group receiving nipocalimab and a placebo group receiving an inactive treatment, both administered once weekly. The study timeline spans from randomization during weeks 13 to 18 of pregnancy through delivery and includes follow-up through the neonatal period and beyond. Participants will undergo various assessments including lab tests, fetal DNA testing, and monitoring of maternal and neonatal health outcomes. Researchers will measure the percentage of pregnancies without fetal loss, intrauterine transfusions, hydrops fetalis, or neonatal death, among many other maternal and infant health parameters. Follow-up extends to 104 weeks for some infant assessments, including growth and development, while maternal safety and pregnancy complications are also monitored up to 24 weeks postpartum. This comprehensive monitoring aims to capture the effect of nipocalimab on both mother and baby throughout pregnancy and after birth.

Age: 18Years - 45YearsFEMALEPhase 3
69 locations
S

Actively Recruiting

Researchers are evaluating whether combining pasritamig with docetaxel can extend the time before disease progression, measured by scans or death, compared to docetaxel alone in adults with metastatic castration-resistant prostate cancer. This type of prostate cancer continues to grow despite low male hormone levels. The study is a Phase 3 randomized trial designed to compare these treatments in this patient population. Participants are assigned to one of two groups. One group receives pasritamig together with docetaxel until disease progression or treatment end. The other group receives docetaxel plus prednisone or prednisolone as background medication. The study uses imaging scans and other criteria to monitor disease progression. The study treatment continues until certain protocol-defined endpoints are met. During the study, participants undergo various scans including CT, MRI, and bone scans to assess disease status. Researchers monitor progression-free survival and other outcomes such as overall survival, symptom progression, and quality of life using questionnaires. Safety is tracked by recording adverse events, lab abnormalities, and treatment side effects. Follow-up lasts up to about four and a half years, allowing comprehensive evaluation of treatment impact and safety.

Age: 18Years +All GendersPhase 3
165 locations
P

Actively Recruiting

Researchers are evaluating whether adding liver stereotactic ablative radiotherapy L-SABR to the usual drug treatment improves outcomes for people with metastatic non-small cell lung cancer NSCLC. This Phase II trial focuses on patients with stage IV NSCLC who have liver metastases and aims to compare the effectiveness of combined radiation and drug therapy versus drug therapy alone. Participants are randomly assigned to one of two groups. One group receives the standard treatment with anti-PD-L1 based immunotherapy, which may include platinum-based chemotherapy, while also undergoing liver stereotactic ablative radiotherapy L-SABR. L-SABR is delivered during a week when no chemotherapy is given and can be scheduled alongside immunotherapy. The other group receives only the standard immunotherapy and chemotherapy without radiation. During the study, participants will be monitored for progression-free survival over up to four years. Researchers will assess liver function, overall health status using the ECOG Performance Scale, and treatment response. Safety and effectiveness are tracked through regular clinical evaluations and laboratory tests. The study is led by Memorial Sloan Kettering Cancer Center and participation lasts according to treatment and follow-up schedules.

Age: 18Years +All GendersPhase 2
9 locations

1-10 of 129

1